The results of the ACCESS PTS trial have been presented at the Society for Vascular Medicine 28th Annual Scientific Sessions (14–17 June, New Orleans, USA). The study found chronic deep vein thrombosis (DVT) patients with post-thrombotic syndrome (PTS) can be treated safely and effectively with EKOS therapy. The ACCESS PTS protocol using EKOS therapy is now the only treatment regimen proven to significantly reduce the signs and symptoms of PTS and show a significant improvement in quality of life.
Endovenous adhesive closure systems are a useful adjunct to thermal ablation treatment for varicose veins, but it is vital that the possible side-effects of such treatments are discussed openly with patients pre-procedurally, according to a presentation at the European Venous Forum (EVF; 29 June–1 July, Porto, Portugal).
Bio2 Medical has announced the results of the Angel Catheter pivotal study published in the Journal of Vascular and Interventional Radiology. The Angel Catheter met all safety endpoints and demonstrated a significant reduction in clinically significant and fatal pulmonary embolism (PE).
The US Food and Drug Administration (FDA) has accepted, for priority review, a supplemental new drug application (sNDA) for Janssen’s Xarelto (rivaroxaban), to include a 10mg once-daily dose for reducing the risk of venous thromboembolism (VTE) after at least six months of standard anticoagulant therapy.
Bluegrass Vascular Technologies has enrolled over one third of its patients in the company’s post-market SAVE (Surfacer System to Facilitate Access in Venous Occlusions) clinical study. The SAVE study is an international, prospective, multicentre clinical follow-up study designed to confirm clinical performance and safety of the Surfacer inside-out access catheter system, a device indicated for obtaining central venous access to facilitate catheter insertion into the central venous system in patients with chronically occluded veins.
The first results from the GARFIELD-VTE (Global anticoagulant registry in the field—venous thromboembolism) were presented at the International Society on Thrombosis and Haemostasis Congress 2017 (8–13 July, Berlin, Germany) providing a contemporary picture of VTE management worldwide.
A study presented at the American Venous Forum (AVF; 14–17 February, New Orleans, USA) suggests that secondary interventions for primary iliac vein stenting are “associated with good outcomes,” with a rate of 10.2% reported.
A presentation at the American Venous Forum (AVF; 14–17 February, New Orleans, USA) has attempted to shed light on what could be an underdiagnosed cause of pelvic pain caused by pelvic venous insufficiency—iliac vein compression.
Medtronic has completed the previously announced sale of a number of its businesses to Cardinal Health, including its Deep Vein Thrombosis (compression) division. The transaction was worth US$6.1 billion.
New evidence suggests that minimally invasive methods to ablate superficial venous reflux in patients with end-stage venous insufficiency are as effective as traditional open venous stripping.
Researchers at North Carolina State University (Raleigh, USA) and the University of North Carolina at Chapel Hill (Chapel Hill, USA) have developed a new surgical tool that uses low-frequency intravascular ultrasound to break down blood clots that cause deep vein thrombosis.
Results from the OPTALYSE PE trial have been presented at the American Thoracic Society International Conference in Washington, DC, USA. The results show that pulmonary embolism (PE) can be treated effectively with EKOS (BTG) over a shorter period and at safer thrombolytic doses compared with the current treatment standard, which will allow for scheduling flexibility and efficiencies in clinician time and drug costs.
Teleflex has announced a new three-year product category contract with Vizient for non-tunnelled central venous catheters. Vizient is the largest member-driven health care performance improvement company in the USA.
The UK’s Information Commissioner’s Office (ICO) has found that the Royal Free National Health Service (NHS) Foundation Trust (London, UK) did not adhere to the UK’s Data Protection Act when it provided patient details to Google DeepMind.
The US Food and Drug Administration (FDA) has approved betrixaban (Bevyxxa, Portola), the first and only anticoagulant for hospital and extended duration prophylaxis (35 to 42 days) of venous thromboembolism (VTE) in adult patients hospitalised for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos